MaxiVAX SA

MaxiVAX is a Geneva-based biotech company developing the first active immunotherapy based on encapsulated cells for treating cancers. The field of Immuno-Oncology has recently seen successes of first generation cancer immunotherapies which are paving the way for MaxiVAX’ novel and competitive approach. The company’s mission is to develop alternative solutions to established cancer therapies that are more effective, personalized, and enable the patient to fight his/her own disease.